<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>isfcppharmaspire</PublisherName>
      <JournalTitle>Pharmaspire</JournalTitle>
      <PISSN>C</PISSN>
      <EISSN>o</EISSN>
      <Volume-Issue>Volume 12, Issue 3</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>July-September, 2020</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>2022</Year>
        <Month>06</Month>
        <Day>10</Day>
      </PubDate>
      <ArticleType>Pharmaceutics</ArticleType>
      <ArticleTitle>Formulation and optimization of fluconazole polymer-lipid hybrid nanoparticles</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>100</FirstPage>
      <LastPage>103</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Iti</FirstName>
          <LastName>Singh</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Shikha</FirstName>
          <LastName>Yadav</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Pooja A.</FirstName>
          <LastName>Chawla</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Manish Pal</FirstName>
          <LastName>Singh</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Viney</FirstName>
          <LastName>Chawla</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Background: Fluconazole is an antifungal drug that is effective both through systemic and topical route. Its bioavailability through the oral route is limited due to its solubility. Polymer-lipid hybrid-based alternative drug delivery system will result in improved oral bioavailability. Objective: The present study deals with the development and evaluation of fluconazole-loaded polymer-lipid hybrid nanoparticles for oral administration. Materials and Methods: Fluconazole-loaded polymer-lipid hybrid nanoparticles were prepared by the solvent emulsification method using dichloromethane as the solvent, stearic acid as lipid, and polyvinyl alcohol as the polymer. The prepared nanoparticles were characterized for particle size, polydispersity index, entrapment efficiency, and in-vitro drug release. Results: Average size and polydispersity index of optimized formulation F5 were 237.0 ---PlusMinusSymbol--- 3.3 nm and 0.345, respectively. The entrapment efficiency of formulation F5 was found to be 86.70%. Conclusion: These results reveal the potential application of novel fluconazole-PLH in the treatment of fungal infections</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Fluconazole, polymer-lipid carriers, Factorial design, polydispersity index, solvent emulsification method.</Keywords>
      <URLs>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13818&amp;title=Formulation and optimization of fluconazole polymer-lipid hybrid nanoparticles</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>1. Tushar D, Nimbalkar V, Kamat J, Mittal A, Mahato RI, Chitkara D. Lipidpolymer hybrid nanocarriers for delivering cancer therapeutics. J Control Rel 2018;271:60-73.&#13;
&#13;
2. Anubhab M, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipidpolymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives. Int J Nanomed 2019;14:1937.&#13;
&#13;
3. Chengyu W, Mu H. Lipid and PLGA microparticles for sustained delivery of protein and peptide drugs. Pharm Nanotech 2020;8:22-32.&#13;
&#13;
4. Liangfang Z, Chan JM, Gu FX, Rhee JW, Wang AZ, Aleksandar F, et al. Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2008;2:1696-702.&#13;
&#13;
5. Thanki K, Papai S, Lokras A, Rose F, Falkenberg E, Franzyk H, et al. Application of a quality-by-design approach to optimise lipid-polymer hybrid nanoparticles loaded with a splice-correction antisense oligonucleotide: Maximising loading and intracellular delivery. Pharm Res 2019;36:37.&#13;
&#13;
6. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6.&#13;
&#13;
7. Government of India. Fluconazole in Indian Pharmacopoeia. Vol. 2. New Delhi: Government of India. 2018. p. 2065-6.&#13;
&#13;
8. De M, James E. Basic Statistics and Pharmaceutical Statistical Applications. United States: CRC Press; 2014.&#13;
&#13;
9. Small GW. In: Silverstein RM, Bassler GC, Morrill TC, editors. Spectrometric Identification of Organic Compounds. 5th ed. New York: Wiley; 1991.&#13;
&#13;
10. Jie C, Huang H, Song W, Hu H, Chen J, Zhang L, et al. Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharm 2015;495:728-37.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>